ONCT News and Press, Oncternal Therapeutics Inc. From 11/16/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated One of two patients at the current, highest TK216 exposure dose regimen has experienced a deep and sustained clinical response Dose-finding and schedule escalation cohor...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthc...

Oncternal Therapeutics, Inc. (ONCT) Q3 2019 Earnings Conference Call November 7, 2019 5:00 P.M. ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President and Chief Executive Officer Frank Hsu - Chief Medical Officer Conference Call Partici...

Oncternal Therapeutics (NASDAQ: ONCT ): Q3 GAAP EPS of -$0.32. Revenue of $0.54M (+63.6% Y/Y) Press Release More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion cohort in patients with MCL, based on encouraging interim clinical results Reported first sustained objective response in patient with Ewing sarcoma tre...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted small molecule inhibitor of ETS transcription factor oncoproteins &#x...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019. Oncter...

Gainers: NF Energy Saving (NASDAQ: BIMI ) +286% . Synthesis Energy Systems (NASDAQ: SES ) +156% . Yuma Energy (NYSEMKT: YUMA ) +58% . Ideal Power (NASDAQ: IPWR ) +34% . Oncternal Therapeutics (NASDAQ: ONCT ) +31% . Bio-Path Holdings (NASDAQ: BPTH ) +21% . Enochian Biosciences (NASDA...

Oncternal Therapeutics ( ONCT ) may be a good speculative biotech to look into. That's because it has been able to develop a monoclonal antibody, known as cirmtuzumab, which targets the ROR1 protein. The targeting of this ROR1 protein allows cirmtuzumab to be explored in a couple of other comb...